PROCEEDINGS VOLUME 2625
BIOS EUROPE '95 | 12-16 SEPTEMBER 1995
Photochemotherapy: Photodynamic Therapy and Other Modalities
BIOS EUROPE '95
12-16 September 1995
Barcelona, Spain
Progress in the Development of Tumor Photosensitizers
Proc. SPIE 2625, Photodynamic therapy with 5-aminolevulinic acid: basic principles and applications, 0000 (31 January 1996); doi: 10.1117/12.230940
Proc. SPIE 2625, Benzoporphyrins as photosenitizers for the photodynamic therapy of cancer, 0000 (31 January 1996); doi: 10.1117/12.230955
Proc. SPIE 2625, Synthesis and properties of new chlorin and bacteriochlorin photosensitizers, 0000 (31 January 1996); doi: 10.1117/12.230970
Proc. SPIE 2625, Uptake and photodynamic activity of porphycenes in tumor cells implanted on the chick chorioallantoic membrane (CAM), 0000 (31 January 1996); doi: 10.1117/12.230977
Free Communications I
Proc. SPIE 2625, Wavelength-dependent in-vitro and in-vivo photodynamic effects after sensitization with 5-aminolevulinic acid induced protoporphyrin IX, 0000 (31 January 1996); doi: 10.1117/12.230993
Proc. SPIE 2625, Topical photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic keratoses: a first clinical study, 0000 (31 January 1996); doi: 10.1117/12.231002
Proc. SPIE 2625, Effect of desferrioxamine on production of ALA-induced Protoporphyrin IX in normal mouse skin, 0000 (31 January 1996); doi: 10.1117/12.230941
Proc. SPIE 2625, Differential cell photosensitivity in photodynamic therapy of the rat endometrium, 0000 (31 January 1996); doi: 10.1117/12.230950
Proc. SPIE 2625, Whole bladder wall photodynamic therapy using 5-ALA: an experimental study in pigs, 0000 (31 January 1996); doi: 10.1117/12.230951
Poster Session
Proc. SPIE 2625, Photodynamic therapy of human bladder carcinoma cells in vitro with liposomes as carrier for porphycene: 9-acetamido-2,7,12,17-tetra-n-propylporphycene (AamTPPn), 0000 (31 January 1996); doi: 10.1117/12.230952
Proc. SPIE 2625, 9-acetoxy-2,7,12,17-tetrakis-(B-methoxyethyl)-porphycene (ATMPn): a novel photosensitizer for photodynamic therapy--intracellular uptake and distribution in vitro, 0000 (31 January 1996); doi: 10.1117/12.230953
Proc. SPIE 2625, 9-acetoxy-2,7,12,17-tetrakis-(B-methoxyethyl)-porphycene (ATMPn): a novel photosensitizer for photodynamic therapy--dose-dependent effects in vitro, 0000 (31 January 1996); doi: 10.1117/12.230954
Proc. SPIE 2625, Monofunctional phthalocyanine derivatives as potential sensitizers for PDT, 0000 (31 January 1996); doi: 10.1117/12.230956
Proc. SPIE 2625, Carrier systems in PDT II: accumulation strategies of biotin-avidin coupled photosensitizers developed on cultured tumor cells, 0000 (31 January 1996); doi: 10.1117/12.230957
Proc. SPIE 2625, Peripheral substitution of pheophorbides and bacteriopheophorbides to promote inclusion into inert carrier systems for PDT, 0000 (31 January 1996); doi: 10.1117/12.230958
Free Communications II
Proc. SPIE 2625, Photophysical properties of pheophorbide-a in different carrier-systems, 0000 (31 January 1996); doi: 10.1117/12.230959
Poster Session
Proc. SPIE 2625, Photomodification of Hp accumulated in erythrocyte cell ghosts, 0000 (31 January 1996); doi: 10.1117/12.230960
Proc. SPIE 2625, Light-induced processes in aqueous solutions of porphyrins, 0000 (31 January 1996); doi: 10.1117/12.230961
Proc. SPIE 2625, Mechanism of in-vivo photodynamic effects, 0000 (31 January 1996); doi: 10.1117/12.230962
Proc. SPIE 2625, Volume changes of human endothelial cells induced by photodynamic treatment, 0000 (31 January 1996); doi: 10.1117/12.230963
Free Communications II
Proc. SPIE 2625, Photodegradation of sensitizers in mouse skin during PCT, 0000 (31 January 1996); doi: 10.1117/12.230964
Poster Session
Proc. SPIE 2625, Synthesis of NIR-absorbing monofunctionalized pthalocyanines via copolymer coupling, 0000 (31 January 1996); doi: 10.1117/12.230965
Free Communications I
Proc. SPIE 2625, Photobleaching of the photosensitizers octa-<alpha>-butyloxy-zincphthalocyanine and 132-hydroxy-bacteriopheophorbide-a-methylester, 0000 (31 January 1996); doi: 10.1117/12.230966
Poster Session
Proc. SPIE 2625, Cellular uptake kinetics and photodynamic activity of meso-tetrahydroxyphenylchlorin (mTHPC), 0000 (31 January 1996); doi: 10.1117/12.230967
Free Communications II
Proc. SPIE 2625, Dynamic fluorescence changes of hydrophilic and lipophilic phthalocyanines during PDT in vivo and in vitro, 0000 (31 January 1996); doi: 10.1117/12.230968
Poster Session
Proc. SPIE 2625, Theoretical description of interactions between some tetrapyrroles and cyclodextrin dimers, 0000 (31 January 1996); doi: 10.1117/12.230969
Proc. SPIE 2625, Flourescence analysis of ALA-induced Protoporphyrin IX in psoriatic plaque, 0000 (31 January 1996); doi: 10.1117/12.230971
Proc. SPIE 2625, Rate-equation analysis of Protoporphyrin IX photo-oxidation, 0000 (31 January 1996); doi: 10.1117/12.230972
Proc. SPIE 2625, Can ultrasounds induce cytotoxicity in presence of hematoporphyrin derivative as photodynamic therapy?, 0000 (31 January 1996); doi: 10.1117/12.230973
Effects of Photodynamic Therapy at the Cell and Tissue Levels
Proc. SPIE 2625, Clinical status of benzoporphyrin derivative, 0000 (31 January 1996); doi: 10.1117/12.230974
Proc. SPIE 2625, Uptake, subcellular localization, and phototoxicity of photosensitizing porphyrins, 0000 (31 January 1996); doi: 10.1117/12.230975
Proc. SPIE 2625, Silicon naphthalocyanines derivatives: delivery systems as modulators of pharmacokinetics and photodynamic therapy (PDT) outcomes, 0000 (31 January 1996); doi: 10.1117/12.230976
Free Communications II
Proc. SPIE 2625, Interspecies pharmacokinetics as applied to the hard drug photosensitizing agent meta(tetrahydroxphenyl)chlorin, 0000 (31 January 1996); doi: 10.1117/12.230978
Poster Session
Proc. SPIE 2625, Comparison of two phthalocyanines for PDT, 0000 (31 January 1996); doi: 10.1117/12.230979
Free Communications II
Proc. SPIE 2625, Independent pathway for inclusion complexes of porphyrinoid drugs in tumors: the separation from the lipoprotein pathway in plasma, 0000 (31 January 1996); doi: 10.1117/12.230980
Proc. SPIE 2625, Distribution of chlorin-e6 derivatives in biological systems: investigation of pH-effect, 0000 (31 January 1996); doi: 10.1117/12.230981
Proc. SPIE 2625, Photodynamic activity of porphines on tubulin assembly, 0000 (31 January 1996); doi: 10.1117/12.230982
Proc. SPIE 2625, Targeting of the tumor microcirculation with a new photosensitizer, 0000 (31 January 1996); doi: 10.1117/12.230983
Proc. SPIE 2625, Enhancement of the efficiency of photodynamic therapy by combination with the microtubule inhibitor vincristine, 0000 (31 January 1996); doi: 10.1117/12.230984
Poster Session
Proc. SPIE 2625, Measurements of light penetration into human tissues in vivo, 0000 (31 January 1996); doi: 10.1117/12.230985
Free Communications II
Proc. SPIE 2625, Skin photosensitivity as a model in photodynamic therapy, 0000 (31 January 1996); doi: 10.1117/12.230986
Proc. SPIE 2625, Enhanced antitumoral efficacy by intratumoral perfusion of activated macrophages associated with photodynamic therapy, 0000 (31 January 1996); doi: 10.1117/12.230987
Proc. SPIE 2625, Clinical results of a new high-phototherapeutic-efficiency blue-green lamp for the management of hyperbilirubinemia, 0000 (31 January 1996); doi: 10.1117/12.230988
Poster Session
Proc. SPIE 2625, In-vivo interleukin-1-alpha induction following chlorin-e6 photodynamic therapy in Balb/c mice, 0000 (31 January 1996); doi: 10.1117/12.230989
Proc. SPIE 2625, Indicators of metastatic potential induced by low-power irradiation at photosensitizer threshold dose in mouse melanoma M2R, 0000 (31 January 1996); doi: 10.1117/12.230990
Proc. SPIE 2625, Photodynamic therapy of human malignant tumors: a comparative study between photohem and tetrasulfonated aluminum phthalocyanine, 0000 (31 January 1996); doi: 10.1117/12.230991
Proc. SPIE 2625, Photodynamic therapy of gastric cancer, 0000 (31 January 1996); doi: 10.1117/12.230992
Proc. SPIE 2625, Photodynamic and selective therapy: experimental and clinical study, 0000 (31 January 1996); doi: 10.1117/12.230995
Proc. SPIE 2625, Immune and antioxidizing response in cancer patients to photodynamic therapy with photohem and photosens as photosensitizers, 0000 (31 January 1996); doi: 10.1117/12.230996
Proc. SPIE 2625, Photodynamic therapy of early stage cancer of lung, esophagus, and stomach with two different photosensitizers, 0000 (31 January 1996); doi: 10.1117/12.230997
Proc. SPIE 2625, Fluorescence examinations of patients with tumors of diferent localizations in the course of photodynamic therapy with photosensitizer photosens, 0000 (31 January 1996); doi: 10.1117/12.230998
Proc. SPIE 2625, Palliative treatment of patients with malignant structures of esophagus, 0000 (31 January 1996); doi: 10.1117/12.230999
Proc. SPIE 2625, Photodynamic therapy of spread skin malignancies with scanning electron-beam-pumped semiconductor laser, 0000 (31 January 1996); doi: 10.1117/12.231000
Free Communications II
Proc. SPIE 2625, Interstitial photodynamic therapy of canine prostate with meso-tetra-(m-hydroxyphenyl) chlorin and 5-aminolevulinic acid: a preliminary study, 0000 (31 January 1996); doi: 10.1117/12.231001
Poster Session
Proc. SPIE 2625, Phototoxicity, dark-toxicity, and uptake-kinetics of natural hydrophilic and hydrophobic porphyrins in endothelial cells, 0000 (31 January 1996); doi: 10.1117/12.231003